Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, at the 2024 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101’s Potential in IGF-1R Prominent Cancers
February 26, 2024 08:00 ET
|
Lirum Therapeutics, Inc.
New York, NY, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases,...
Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas
October 31, 2023 13:27 ET
|
Lirum Therapeutics, Inc.
New York, NY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today...